Anlon Healthcare Peer Comparison
NSE: AHCL | BSE: 544497
₹15.91
₹0.31
(1.99%)
As on 28-Aug-2026IST
Market cap
₹846 Cr
Revenue (TTM)
₹174 Cr
P/E Ratio
29.1
P/B Ratio
3.2
Div. Yield
0 %
Edit
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
846 | 35,497 | 29,798 | 16,589 | 15,507 |
Revenue (₹ Cr) |
174 | 9,683 | 2,372 | 2,590 | 1,108 |
Net Profit (₹ Cr) |
29.06 | 1,018.97 | 497.77 | 603.02 | 270.18 |
Net Margin (%) |
16.65 | 10.47 | 20.72 | 22.63 | 23.29 |
RoE (%) |
13.70 | 21.30 | 28.49 | 19.61 | 14.45 |
Price to Earnings |
29.12 | 35.10 | 59.86 | 27.51 | 56.31 |
Price-To-Book |
3.16 | 6.77 | 14.74 | 4.76 | 7.48 |
Income Statement (₹ Cr)
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
171.97 | 9,203.54 | 2,022.99 | 2,551.83 | 1,054.89 |
|
Total Income
|
172.22 | 9,335.01 | 2,053.15 | 2,612.24 | 1,107.25 |
|
Total Expenditure
|
124.45 | 7,457.80 | 1,448.49 | 1,754.55 | 686.95 |
|
EBITDA
|
47.52 | 1,745.74 | 574.50 | 797.28 | 367.94 |
|
Depreciation
|
1.52 | 415.05 | 91.74 | 75.36 | 74.46 |
|
EBIT
|
45.99 | 1,330.70 | 482.76 | 721.93 | 293.48 |
|
Interest
|
3.74 | 143.67 | 23.95 | 5.37 | 0.82 |
|
Other Income
|
0.26 | 131.47 | 30.17 | 60.41 | 52.36 |
|
Exceptional Items
|
-- | -31.35 | 76.40 | -25.66 | -3.28 |
|
Profit before Tax
|
42.51 | 1,287.14 | 488.98 | 751.31 | 344.65 |
|
Provision for Tax
|
13.42 | 345.87 | 124.98 | 186.83 | 85.42 |
|
Profit after Tax
|
29.09 | 941.27 | 364.00 | 564.48 | 259.23 |
Liabilities (₹ Cr)
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
230.23 | 4,950.03 | 1,874.47 | 3,332.13 | 2,017.06 |
|
Minority Interest
|
24.57 | 26.64 | -- | -- | -1.92 |
|
Non-Current Liabilities
|
11.61 | 584.19 | 345.47 | 142.73 | 47.58 |
|
Current Liabilities
|
107.57 | 3,912.24 | 710.20 | 682.24 | 169.08 |
|
Total Liabilities
|
373.97 | 9,514.48 | 2,930.14 | 4,157.10 | 2,231.79 |
Assets (₹ Cr)
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
65.70 | 3,861.01 | 1,447.01 | 1,333.54 | 981.68 |
|
Current Assets
|
308.26 | 5,612.10 | 1,483.13 | 2,823.56 | 1,250.11 |
|
Total Assets
|
373.97 | 9,514.48 | 2,930.14 | 4,157.10 | 2,231.79 |
|
Total Debt*
|
43.65 | 1,204.08 | 196.61 | 0.00 | 0.00 |
|
Net Current Assets
|
200.69 | 1,699.86 | 772.93 | 2,141.33 | 1,081.03 |
|
Contingent Liabilities
|
0.25 | 258.92 | 13.18 | 4.82 | 3.76 |
Cashflow (₹ Cr)
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-79.44 | 943.55 | 346.68 | 565.41 | 266.88 |
|
Cash Flow from Investing Activities
|
-36.34 | -1,193.06 | -423.73 | -570.15 | -142.72 |
|
Cash from Financing Activities
|
118.69 | 343.43 | 20.98 | -64.34 | -112.88 |
|
Net Cash Inflow / Outflow
|
2.92 | 93.92 | -56.08 | -69.08 | 11.28 |
Ratios
Profitability Ratios
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
21.98 | 25.25 | 27.50 | 24.61 | 18.04 |
|
ROE (%)
|
18.73 | 20.09 | 21.43 | 18.41 | 13.54 |
|
ROA (%)
|
10.48 | 10.70 | 14.25 | 14.27 | 12.15 |
|
EBIT Margin (%)
|
27.78 | 20.40 | 29.89 | 33.61 | 39.84 |
|
Net Margin (%)
|
16.89 | 10.08 | 17.73 | 21.61 | 23.41 |
|
Cash Profit Margin (%)
|
17.80 | 14.44 | 22.53 | 24.81 | 31.63 |
Growth Ratios
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
42.96 | 16.56 | 36.98 | 6.91 | -12.10 |
|
EBIT Growth (%)
|
47.55 | 21.77 | 75.89 | 19.60 | -23.76 |
|
Net Profit Growth (%)
|
41.77 | 33.05 | 39.94 | 16.24 | -30.25 |
|
EPS Growth (%)
|
4.20 | 35.59 | 39.94 | 16.05 | -29.80 |
|
Book Value Growth (%)
|
186.28 | 11.36 | 22.95 | 18.43 | 11.27 |
Valuation Ratios
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
2.07 | 32.73 | 42.34 | 21.18 | 40.73 |
|
Price / Book Value
|
2.57 | 6.13 | 8.23 | 3.60 | 5.27 |
|
Dividend Yield (%)
|
0.00 | 0.23 | 0.28 | 0.51 | 0.74 |
|
EV/EBITDA
|
13.21 | 16.68 | 25.23 | 13.94 | 25.25 |
|
Market Cap (₹ Cr)
|
591.58 | 30,257.56 | 15,412.11 | 11,956.86 | 10,627.92 |
Solvency Ratios
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.19 | 0.24 | 0.10 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.16 | 0.16 | -- | -- | 0.00 |
|
Current Ratio
|
2.87 | 1.43 | 2.09 | 4.14 | 7.39 |
|
Quick Ratio
|
1.81 | 0.82 | 1.37 | 3.12 | 5.46 |
|
Interest Coverage
|
12.36 | 9.96 | 21.42 | 140.86 | 419.57 |
Operating Efficiency Ratios
| Anlon Healthcare | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
60.29 | 27.84 | 26.76 | 42.05 | 43.63 |
|
Asset Turnover
|
0.62 | 1.07 | 0.79 | 0.65 | 0.49 |
|
Receivable days
|
189.62 | 88.68 | 77.32 | 144.58 | 169.86 |
|
Inventory Days
|
173.44 | 84.11 | 80.83 | 96.67 | 97.92 |
|
Payable days
|
107.37 | 176.65 | 125.94 | 135.45 | 159.68 |
|
Cash Conversion Cycle
|
255.69 | -3.86 | 32.22 | 105.80 | 108.11 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
